These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30797042)

  • 41. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

  • 42. Patient experiences of buprenorphine dispensing from a mobile medical unit.
    Messmer SE; Elmes AT; Infante AF; Patterson A; Smith M; Murphy AL; Jimenez AD; Mayer S; Watson DP; Whitfield K; Fisher SJ; Jarrett JB
    Addict Sci Clin Pract; 2024 Jul; 19(1):53. PubMed ID: 39026326
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pain is not associated with worse office-based buprenorphine treatment outcomes.
    Fox AD; Sohler NL; Starrels JL; Ning Y; Giovanniello A; Cunningham CO
    Subst Abus; 2012; 33(4):361-5. PubMed ID: 22989279
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Extended-release versus oral buprenorphine as opioid maintenance treatment during pregnancy-maternal and neonatal outcomes.
    Kanervo M; Tupola S; Nikkola E; Rantakari K; Kahila H
    Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():106-110. PubMed ID: 38608352
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of a sequential multiple assignment randomized trial to test contingency management and an integrated behavioral economic and mindfulness intervention for buprenorphine-naloxone medication adherence for opioid use disorder.
    Peter SC; Murphy JG; Witkiewitz K; Hand SB; Thomas F; Johnson KC; Cowan R; Harris M; Derefinko KJ
    Trials; 2023 Mar; 24(1):237. PubMed ID: 36991453
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of behavioral treatment conditions in buprenorphine maintenance.
    Ling W; Hillhouse M; Ang A; Jenkins J; Fahey J
    Addiction; 2013 Oct; 108(10):1788-98. PubMed ID: 23734858
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Initiating buprenorphine treatment for opioid use disorder during short-term in-patient 'detoxification': a randomized clinical trial.
    Stein M; Herman D; Conti M; Anderson B; Bailey G
    Addiction; 2020 Jan; 115(1):82-94. PubMed ID: 31430414
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
    Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
    Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Methadone maintenance treatment may improve completion rates and delay opioid relapse for opioid dependent individuals under community corrections supervision.
    Clark CB; Hendricks PS; Lane PS; Trent L; Cropsey KL
    Addict Behav; 2014 Dec; 39(12):1736-40. PubMed ID: 25117851
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Within-subject evaluation of interim buprenorphine treatment during waitlist delays.
    Oleskowicz TN; Ochalek TA; Peck KR; Badger GJ; Sigmon SC
    Drug Alcohol Depend; 2021 Mar; 220():108532. PubMed ID: 33508690
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences.
    Neale J; Tompkins CNE; Strang J
    Drug Alcohol Rev; 2019 Jul; 38(5):510-518. PubMed ID: 31131514
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
    Rolland B; Trojak B; Nourredine M; Bachellier J; Chappuy M; Bendimerad P; Kosim M; Hjelmström P; Meroueh F; Nubukpo P; Brousse G
    Drug Alcohol Depend; 2021 Mar; 220():108492. PubMed ID: 33482572
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Video directly observed therapy for patients receiving office-based buprenorphine - A pilot randomized controlled trial.
    Tsui JI; Leroux BG; Radick AC; Schramm ZA; Blalock K; Labelle C; Heerema M; Klein JW; Merrill JO; Saxon AJ; Samet JH; Kim TW
    Drug Alcohol Depend; 2021 Oct; 227():108917. PubMed ID: 34399136
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.
    Otiashvili D; Piralishvili G; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
    Drug Alcohol Depend; 2013 Dec; 133(2):376-82. PubMed ID: 23916321
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A mixed-methods analysis of patient safety incidents involving opioid substitution treatment with methadone or buprenorphine in community-based care in England and Wales.
    Gibson R; MacLeod N; Donaldson LJ; Williams H; Hibbert P; Parry G; Bhatt J; Sheikh A; Carson-Stevens A
    Addiction; 2020 Nov; 115(11):2066-2076. PubMed ID: 32149443
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.
    Sigmon SC; Bigelow GE
    Addiction; 2017 Mar; 112(3):386-387. PubMed ID: 27561982
    [No Abstract]   [Full Text] [Related]  

  • 58. Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence.
    Jackson H; Mandell K; Johnson K; Chatterjee D; Vanness DJ
    Subst Abus; 2015; 36(2):226-31. PubMed ID: 25775099
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.
    DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA
    Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Group medication management for buprenorphine/naloxone in opioid-dependent veterans.
    Berger R; Pulido C; Lacro J; Groban S; Robinson S
    J Addict Med; 2014; 8(6):415-20. PubMed ID: 25275875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.